Moreover, this combination therapy increased the expression of multiple tumor-homing receptors and the SLAM-associated protein (SAP) in CD8+ TILs, including sele (Selectin-E), Itgae (CD103), and SAP-related genes, which are essential for T cell migration signaling and antigen-driven T cell activity, respectively. The gene discussed is SH2D1A; the disease is neoplasm.